Advanced Solid Tumors
Beigene Ltd. supports clinical research in advanced and metastatic solid tumors, with an emphasis on immuno-oncology combinations and novel pathway-targeted agents.
- Anti-PD-1–based combination therapy
- TIGIT and other immune checkpoint targets
- Antitumor activity in selected solid tumor types
The sponsor’s research in this area includes treatment approaches for difficult-to-treat solid malignancies across multiple tumor settings.
Lung and Head and Neck Cancers
Clinical activity includes studies in non-small cell lung cancer, locally advanced, unresectable, or metastatic non-small cell lung cancer, and head and neck squamous cell cancer.
- Non-small cell lung cancer
- Head and neck squamous cell carcinoma
- Checkpoint inhibitor combinations
These programs focus on immunotherapy strategies for cancers with substantial unmet clinical need.
Lymphoid Malignancies
The sponsor funds research in mature B-cell malignancies and relapsed/refractory follicular lymphoma, reflecting a strong interest in hematologic oncology.
- Follicular lymphoma
- B-cell malignancies
- BCL-2 and BTK-directed therapy
Work in this domain includes targeted approaches for lymphoma and related B-cell cancers.
Renal Cancer
Beigene Ltd. also supports studies in renal cell carcinoma, extending its oncology portfolio into genitourinary cancer research.
- Renal cell carcinoma
- Solid tumor immunotherapy
- Combination oncology regimens
This area aligns with broader investigation of targeted and immune-based cancer treatments.
